2,9-dimethyl-1,9-dihydro-purin-6-one | 31010-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2,9-dimethyl-1,9-dihydro-purin-6-one
• 英文别名: 2,9-Dimethyl-1,9-dihydro-purin-6-on；6H-Purin-6-one, 1,9-dihydro-2,9-dimethyl-；2,9-dimethyl-1H-purin-6-one
• CAS: 31010-49-8
• 化学式: C₇H₈N₄O
• mdl: MFCD18801086
• 分子量: 164.167
• InChiKey: YNZFJSLCXTWIDR-UHFFFAOYSA-N

物化性质

• 熔点：
  330 °C (decomp)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(4-amino-2-methyl-6-methylamino-pyrimidin-5-yl)-thioformamide 在 喹啉 、 溶剂黄146 、 sodium nitrite 作用下， 生成 2,9-dimethyl-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  Baddiley et al., Journal of the Chemical Society, 1944, p. 318,321

  摘要：

  DOI：

文献信息

• EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
  申请人：SAREPTA THERAPEUTICS, INC.

  公开号：US20160040162A1

  公开（公告）日：2016-02-11

  Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.

  抗义RNA分子能够结合到人类肌营养不良蛋白基因中的特定靶位点，诱导外显子53跳跃。
• SULFAMIDE AND SULFAMATE INHIBITORS OF hHint1
  申请人：Wagner Carston R.

  公开号：US20180065965A1

  公开（公告）日：2018-03-08

  Embodiments provide, among things, compounds of the formula I and methods for using such compounds to reduce pain (e.g., neuronal pain), treat a mammal's addiction to nicotine or anti-pain drugs, and increase a mammal's sensitivity to drugs that bind MOR or NMDAR.

  实施例提供了一些化合物I的公式和使用这些化合物来减轻疼痛（例如神经性疼痛）、治疗哺乳动物对尼古丁或镇痛药物的成瘾，并增加哺乳动物对结合MOR或NMDAR的药物的敏感性的方法。
• Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
  申请人：Cheng Yung-chi

  公开号：US20100048500A1

  公开（公告）日：2010-02-25

  The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.

  本发明涉及按照一般公式I、II、III、IV或V的新化合物，其中B是核苷酸碱基，其结构如下：其余变量如规范中定义，并且包括这些化合物的制药组合物。这些化合物可作为抗病毒制剂在病毒治疗中使用。
• INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
  申请人：Sadhu Chanchal

  公开号：US20120172591A1

  公开（公告）日：2012-07-05

  Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

  本发明揭示了抑制磷脂酰肌醇3-激酶δ亚型（PI3Kδ）活性的方法，以及治疗免疫和炎症等疾病的方法，其中PI3Kδ在白细胞功能中发挥作用。优选地，这些方法采用能够选择性地抑制PI3Kδ而不显著抑制其他PI3K亚型活性的活性剂。提供了抑制PI3Kδ活性的化合物，包括选择性抑制PI3Kδ活性的化合物。还提供了使用PI3Kδ抑制剂化合物抑制癌细胞生长或增殖的方法。因此，本发明提供了使用PI3Kδ抑制剂化合物在体外和体内抑制PI3Kδ介导的过程的方法。
• INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
  申请人：SADHU Chanchal

  公开号：US20100152211A1

  公开（公告）日：2010-06-17

  Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

  本文公开了抑制磷脂酰肌醇3-激酶δ亚型（PI3Kδ）活性的方法，以及治疗免疫和炎症等疾病的方法，其中PI3Kδ在白细胞功能中发挥作用。最好的方法是使用能够选择性抑制PI3Kδ的活性剂，同时不显著抑制其他PI3K亚型的活性。提供了抑制PI3Kδ活性的化合物，包括选择性抑制PI3Kδ活性的化合物。还提供了使用PI3Kδ抑制剂化合物抑制癌细胞生长或增殖的方法。因此，本发明提供了使用PI3Kδ抑制剂化合物在体外和体内抑制PI3Kδ介导的过程的方法。